Drug intelligence / Profile preview

NNC0363-1063

Development stage: Phase 1
Lead developer: Novo Nordisk
Modality: Small Molecules
Administration: Subcutaneous

Overview

NNC0363-1063 is an investigational antihyperglycemic drug being developed by Novo Nordisk for the treatment of type 1 diabetes mellitus. It is a new molecular entity currently in phase 1 clinical trials, with studies evaluating its safety, tolerability, pharmacokinetics, and pharmacodynamics in both healthy participants and those with type 1 diabetes. The drug is administered subcutaneously. Its precise mechanism of action has not been disclosed as of the latest updates[1][2][5].

Beyond the preview

Go deeper on NNC0363-1063.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NNC0363-1063.

Explore the full profile